Get 50% OFF This Monsoon!
Unichem Laboratories
No Data Available
Investor Sentiment
Unichem Laboratories Share price and Fundamental Analysis
Key Metrics
Included In
Stock Returns
Stock Heatmap
No Stocks
Smart Score
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
Technicals
Returns Calculator
If you would have investedResearch Report
No Research Report
Corporate Action
Financials
Key Ratios
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Dividend History
5 Year FactSheet
Documents
No Data Available
News
Unichem Laboratories Management and History
Company Management
Unlock Management Data
See Detailed Analysis & Insights
Company History
Unichem Laboratories Ltd is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients. The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division. The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh.
The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The Baddi plant was approved by UK MHRA and MCC (South Africa). The company received ISO 9001:2000 for all their plants and corporate office. Also, they received ISO 14001:2004 certificates for their formulation plants located at Goa, Ghaziabad and Baddi and the corporate office at Mumbai.
Unichem Laboratories Ltd was incorporated in the year 1962. The company was formed by Amrut V Mody to take over a proprietary business set up in 1944 in Mumbai. They made a foreign collaboration with UCB for bulk drugs and set up first formulation plant at Jogeshwari. In the year 1963, they made a tie up with Uni Sankyo Co-Marketing formulations.
In the year 1968, the company set up formulations plant Ghaziabad and in the year 1976, they set up a fine chemicals unit at Roha. In the year 1984, the company entered an agreement with Upjohn and set up Unisearch Ltd. Also, they entered into the anti-biotic segment and launched Ampoxin, an Ampicillin & Claxacillin combination during the year.
In the year 1987, the company entered the Animal Health Care business. In the year 1996, Unichem Exports Ltd and Unisearch Ltd were merged with the Unichem Laboratories Ltd. In the year 1997, the company set up new corporate office at Mumbai and in May 1997, the company's state-of-the-art formulation plant at Bardez, Goa was successfully commissioned and commercial production was started. In the year 1998, their plant at Baddi, Himachal Pradesh for Antibiotics was completed.
In the year 1999, the company set up modern multipurpose bulk drug plant at Roha. In April 1, 1999, the company launched their new Division, namely Foreva catering to Women's Healthcare. In February 2000, they set up their Molecular Generic Division, which launched 23 new products in the two months of the financial year 1999-2000. Also, the company purchased two brands, namely Emcredil and Candizole-T for a total cost of Rs 132 lakh during the financial year 1999-2000.
In the year 2001, the company set up new R&D centre at Mumbai. Also, they set up new Biosciences R&D centre at Bangalore in association with Indian Institute of Sciences for research work in Bio-technology. In April 2002, the company established a joint venture company with Bioglan Generics Ltd, namely Niche Generics Ltd with 60% stake.
During the year 2002-03, they divested their animal healthcare division. They upgraded the Ghaziabad plant with an investment of Rs 250 million. Also, they started a representative office in Kiev, Ukraine. In March 2003, Unichem SA Pty Ltd became a subsidiary of the company. In the year 2004, they restructured Unisearch and launched Unisearch CD Division.
In the year 2005, the company set up a New Pharma Technology Development Center at Goa. Also, they acquired API manufacturing unit at Pithampur. Further, the company set up their second formulations plant at Baddi and production commenced in April 2005. In May 2005 the company disposed off their old factory at Jogeshwari (West) Mumbai for a consideration of Rs 136.50 million. During the year 2005-06, the company set up a wholly owned subsidiary Unichem Pharmaceuticals (USA) Inc, in USA.
During the year 2006-07, the company started Unichem Specialities Division and launched 11 new products in various therapeutic segments. In December 20006, they acquired the remaining 60% stake in Niche Generics Ltd of UK and thus Niche Generics Ltd became a wholly owned subsidiary company.
During the year 2007-08, the company launched Unikare Division, which caters to Dermatology and Allied therapies. They also launched 27 new products in various therapeutic segments during the year. The company has initiated projects including setting up of a Formulation Plant at Sikkim and the expansion of their existing formulation facility at Baddi in Himachal Pradesh.
The Company launched new division focusing on nephrology in cardiology segment during 2009. It commissioned new formulation plant at Sikkim, which is a solid oral dosage form facility, commissioned a new unit at Baddi for manufacturing all dosage forms of Cephalosporin and launched 19 new products during 2010.
In 2011, the Company launched 22 new brands in various in various therapeutic segments. 4 new brands were launched in Cardiac Care, 3 in Dermatology and 2 in Neuropsychiatry amongst others.
During year 2011-12, a Scheme of Arrangement between AVM Capital Services Private Limited, Chevy Capital Services Private Limited, PM Capital Services Private Limited, Pranit Trading Private Limited and Viramrut Trading Private Limited and Unichem Laboratories Limited was approved by the Hon'ble High Court vide Order dated July 12, 2012 and as a result, the Scheme became effective on August 6, 2012.
The Company incorporated a new subsidiary in Ireland taking the total number of subsidiaries to 5 in March, 2012. In 2013, the Company completed dosage formulations facility at SEZ Pithampur and made agreement to sell the same to Mylan Laboratories Limited. During the year 2015, Synchron Research Private Limited became an Associate of Company.
The Company, in December 2017, transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal, and the manufacturing facility at Sikkim together with all assets and liabilities through slump sale on a going concern basis, to Torrent Pharmaceuticals Limited on mutually agreed terms and conditions.
The Company incorporated a Wholly Owned Subsidiary in China on June 27, 2019 under the name 'Younikaimo Pharmaceutical (Shanghai) Private Limited' in 2020.
Unichem Laboratories Share Price
Unichem Laboratories share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Unichem Laboratories Market Cap
Market capitalization of Unichem Laboratories indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Unichem Laboratories is valued compared to its competitors.
Unichem Laboratories PE Ratio
Unichem Laboratories PE ratio helps investors understand what is the market value of each stock compared to Unichem Laboratories 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
Unichem Laboratories PEG Ratio
The PEG ratio of Unichem Laboratories evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Unichem Laboratories ROE (Return on Equity)
Return on Equity (ROE) measures how effectively Unichem Laboratories generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Unichem Laboratories ROCE (Return on Capital Employed)
Return on Capital Employed (ROCE) evaluates the profitability of Unichem Laboratories in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Unichem Laboratories Total Debt
Total debt of Unichem Laboratories shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
Unichem Laboratories Debt to Equity Ratio
The Debt-to-Equity (DE) ratio of Unichem Laboratories compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
Unichem Laboratories CAGR (Compound Annual Growth Rate)
CAGR shows the consistent growth rate of Unichem Laboratories over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Unichem Laboratories Technical Analysis
Technical analysis of Unichem Laboratories helps investors get an insight into when they can enter or exit the stock. Key components of Unichem Laboratories Technical Analysis include:
Support Levels (S1, S2, S3)
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
Resistance Levels (R1, R2, R3)
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Unichem Laboratories shares often struggle to rise above due to selling pressure.
Unichem Laboratories Dividends
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Unichem Laboratories ’s financial health and profitability.
Unichem Laboratories Bonus Shares
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Unichem Laboratories Stock Split
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
Unichem Laboratories Financials
The financials of Unichem Laboratories provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
Unichem Laboratories Profit and Loss Statements
The profit and loss statement of Unichem Laboratories highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Unichem Laboratories .
Unichem Laboratories Balance Sheet
The balance sheet presents a snapshot of Unichem Laboratories ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Unichem Laboratories Cashflow Statements
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
SEBI REGISTERED RESEARCH ANALYST REGISTRATION NUMBER: INH000015729Disclaimer: "Investments in securities are subject to market risks. Read all the related documents carefully before investing." Receiving registration from SEBI and certification from NISM does not assure the performance of the intermediary or guarantee returns to investors in any manner. Compliance/Complaints Email: [email protected]
Features
Portfolio Analysis
Screener
Stock compare
Buckets
Watchlist
Superstar Portfolio
Market
List of BSE200 Companies
List of NIFTY500 Companies
List of NIFTY NEXT 50 Companies
NIFTY Top gainers in 5 Days
NIFTY100 Most Active Stocks
NIFTY Top Gainers in 1 Month